Cogent Biosciences Inc Overview
Cogent Biosciences is a Waltham, Massachusetts–based precision-medicine biotechnology company on the threshold of becoming a commercial-stage oncology and rare-disease company. Its franchise asset, bezuclastinib (CGT9486), is a highly selective tyrosine kinase inhibitor of KIT exon 17 mutations, most importantly KIT D816V, the driver of systemic mastocytosis. During 2025 Cogent delivered positive results from three separate pivotal trials — SUMMIT in non-advanced systemic mastocytosis, APEX in advanced systemic mastocytosis, and the Phase 3 PEAK trial in imatinib-pretreated gastrointestinal stromal tumors, the first positive Phase 3 in second-line GIST in more than twenty years. Three New Drug Applications are now before the FDA, with PDUFA dates of 30 November 2026 (GIST, Priority Review) and 30 December 2026 (NonAdvSM). The company carries no product revenue, roughly $866 million of pro-forma liquidity, and a wholly internally discovered second-wave pipeline spanning ErbB2, PI3Kα, pan-KRAS(ON) and JAK2 V617F. It is, in effect, a single-asset launch story with an optionality tail.
| Metric | FY2020 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Employees (headcount, year-end) | 15 | 164 | 205 | 258 |
Cogent Biosciences describes itself in its own filings as "a biotechnology company focused on developing precision therapies for genetically defined diseases," whose "approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients" (Form 10-K, FY2023, Note 1; language substantially repeated in the FY2025 filings and in the 2026 proxy, which upgrades the self-description to "a late, clinical-stage biotechnology company"). As of the 2026 proxy statement and the August 2026 earnings release, that self-description is in transition: management states that Cogent "will transform Cogent into a fully integrated commercial stage company with plans to launch bezuclastinib in the second half of the year" (2026 milestones release, 12 January 2026).
Independent characterization. Cogent is not a diversified pharmaceutical business. It is a concentrated, single-molecule development company that has, over six years, converted an in-licensed clinical-stage asset acquired from a distressed reverse-merger transaction into a three-indication regulatory package, and has funded that conversion almost entirely through repeated equity issuance into positive clinical news. Everything about the enterprise — its cost structure, its balance sheet, its governance, its valuation — is a function of bezuclastinib. The internally discovered pipeline (ErbB2, PI3Kα, KRAS, JAK2 V617F) is real and is generating INDs, but as of September 2026 it contributes no near-term value inflection and consumes cash.
Revenue model. Cogent has generated no product revenue in any fiscal year from 2021 through 2025 and none in the first half of 2026. Its consolidated statements of operations begin at "Operating expenses" with no revenue line whatsoever (FY2025 and 1H26 statements of operations). Post-approval, the intended model is a single-product, physician-administered oral small-molecule specialty pharmaceutical sold in the United States through a direct field force, with specialty pharmacy/specialty distribution channel economics typical of rare-disease oncology. There is no subscription, service or licensing revenue. Cogent is a net payer of royalties: worldwide rights to bezuclastinib were exclusively licensed by Kiq LLC (which Cogent acquired) from Plexxikon Inc., a member of the Daiichi Sankyo Group, with Plexxikon entitled to an upfront payment, development milestones, and mid- to high-single-digit royalties (Unum/Kiq acquisition press release, 6 July 2020). A milestone payment to Plexxikon was among the non-recurring cash items in Q1 2026 (Q1 2026 earnings release, 5 May 2026).
Value chain position. Cogent is a discovery-and-development originator with an outsourced manufacturing base. It operates its own medicinal chemistry and biology laboratories in Boulder, Colorado, and conducts clinical development globally through CROs and investigator sites. Drug substance and drug product are manufactured by third parties; on 1 September 2026 the company entered a Commercial Supply Agreement with Hovione FarmaCiencia S.A. to manufacture bezuclastinib spray-dried dispersion and bezuclastinib tablets, with an initial five-year term and successive automatic two-year renewals, purchase against rolling quarterly forecasts, and specified minimum-percentage requirements that decline over the term (8-K, 2 September 2026).
Customer types and end markets. The end customers are (i) hematologists and allergist/immunologists treating systemic mastocytosis, and (ii) medical oncologists and sarcoma specialists treating GIST. The economic buyers are U.S. commercial payers, Medicare Part D and Medicaid. The geographic end market at launch is exclusively the United States; no ex-U.S. regulatory filings have been disclosed.
Commercial infrastructure. Management stated in the 2026 proxy that "our commercial organization will ultimately include up to 100 employees inclusive of both home office and field-based employees." By the Q2 2026 release the company had "successfully hired and onboarded all Integrated Business Team members, spanning clinical account managers, patient access navigators and patient educators." Cogent also operates FDA-sanctioned Expanded Access Programs for U.S. GIST and SM patients (FY2025 and Q1 2026 releases).
Strategy
Stated strategy — verbatim themes
From the 2026 proxy statement: the company's governance practices "are designed to support our mission to deliver the next best-in-class therapies for patients with genetically defined diseases." From the Corporate Responsibility section: "Our mission is to deliver the next best-in-class therapies for patients with genetically defined diseases — to move beyond incremental improvements and solely treating symptoms, to address the real causes of disease. We are methodical, rational and intentional in our approach."
From Andrew Robbins, 12 January 2026: "During 2026, we will transform Cogent into a fully integrated commercial stage company with plans to launch bezuclastinib in the second half of the year."
From Robbins, 17 February 2026: "These recent and upcoming milestones underscore the breadth of bezuclastinib's best-in-class potential across KIT-mutant driven diseases. With a very strong balance sheet entering 2026, we will soon finish building our commercial organization and will be ready to launch bezuclastinib in the second half of 2026."
From Robbins, 10 August 2026: "supported by our strong balance sheet, we are well prepared to launch bezuclastinib and advance the standard of care for patients with GIST and Systemic Mastocytosis while continuing to invest in our broader pipeline of precision therapies for genetically defined diseases."
The strategy decomposes into four themes: (i) maximize bezuclastinib across the full KIT-mutant disease spectrum through three simultaneous label positions; (ii) build a single, cross-functional customer-facing organization that can serve both a hematology/allergy audience and a sarcoma-oncology audience; (iii) fund the launch from the balance sheet rather than from a partner, preserving 100% of economics; and (iv) reinvest in a wholly owned discovery engine in Boulder to avoid the single-asset trap.
Strategic initiatives, last 24 months
| Date | Initiative | Detail and strategic intent |
|---|---|---|
| 2024–2025 | Commercial organization build | Target of up to 100 employees across home office and field. CCO hired May 2024; all Integrated Business Team members — clinical account managers, patient access navigators, patient educators — hired and onboarded by August 2026. Headcount rose 205 → 258 during 2025 and continued through 2026 (59 inducement grants in August 2026 alone). |
| July 2025 | Upsized public equity offering | ~$215.8 million net, immediately after positive SUMMIT top-line. Runway extended through anticipated launch and into 2027. |
| Sept 2025 | New three-year PSU programme | Retention through the approval-and-launch transition; performance period ending December 2028, tied to stock-price hurdles or development and commercial milestones. |
| Nov 2025 | Dual equity and convertible financing | $230 million 1.625% converts due 2031 plus 9,677,420 shares at $31.00; net $546.8 million. Deliberately blended instrument choice to limit dilution while extending runway. |
| Q4 2025 | Term-debt retirement | $54.8 million long-term debt repaid; $7.2 million extinguishment loss accepted to clean the capital structure ahead of launch and remove restrictive covenants. |
| Dec 2025 – Jun 2026 | Three sequential NDA submissions | NonAdvSM (Dec 2025), GIST (Apr 2026), AdvSM (Jun 2026). Sequencing designed to stagger review workload and secure the GIST Priority Review slot. |
| Jan 2026 | RTOR and Breakthrough Therapy Designation, GIST | Compressed the GIST review cycle; PDUFA of 30 November 2026 arrives ahead of the NonAdvSM date despite a later submission. |
| Q1 2026 | FGFR programme wind-down | First portfolio pruning of the Cogent era; capital reallocated toward the ErbB2, PI3Kα, KRAS and JAK2 programmes. |
| Q1–Q2 2026 | Two Phase 1 starts | CGT4255 (ErbB2) and CGT6297 (PI3Kα) into dose escalation — the second and third internally discovered molecules to reach the clinic. |
| Q2 2026 | PEAK first-line exon 9 extension cohort | 40-patient single-arm cohort in first-line exon 9 GIST with limited or no imatinib exposure — a life-cycle move to extend bezuclastinib upstream from second line, prospectively testing the 25.1-month mPFS signal from the Phase 3 exon 9 subgroup. |
| Aug 2026 | $400 million ATM programme | Opportunistic, launch-contingent capital flexibility without a marketed follow-on. $73.6 million gross already drawn in July 2026. |
| Sept 2026 | Hovione commercial supply agreement | Five-year initial term with automatic two-year renewals; secures drug substance and tablet supply ahead of PDUFA, with declining minimum-requirement percentages preserving future second-source optionality. |
| Ongoing | Expanded Access Programs | FDA-sanctioned EAPs for U.S. GIST and SM patients at a growing number of sites — builds prescriber familiarity and patient-advocacy goodwill ahead of launch. |
Medium-term financial targets and guidance
Cogent provides no revenue, earnings or margin guidance. The only quantified forward commitment is the cash runway: existing cash, cash equivalents and marketable securities plus the $73.6 million July 2026 ATM proceeds are expected to fund operating expenses and capital expenditure requirements into late 2028, including through potential FDA approvals in GIST, NonAdvSM and AdvSM and early commercial launch activities. The runway guidance has been progressively extended — into 2025 (as of FY2022), into 2027 (as of FY2023 plus the PIPE), into late 2026 (as of FY2024), into 2027 (Q3 2025), into 2028 (FY2025), and into late 2028 (Q2 2026).
Sustainability and ESG commitments
Both facilities are green-certified (Waltham LEED Platinum; Boulder LEED-EB). The Boulder lab uses a lab-exhaust energy recovery system to precondition supply air. Composting and recycling programmes operate at both sites, including recycling of lab plastic waste streams not accepted by the Boulder municipal programme. Commuter benefits include bike-to-work and public transportation subsidies, plus a flexible work-from-home programme for certain roles. Cogent has not published emissions targets, a net-zero commitment, or a standalone sustainability report.
Products & Services
Cogent has no approved or marketed product as of 13 September 2026. The catalog below is therefore a development portfolio. There is no disclosed pricing model for any asset; U.S. list price for bezuclastinib has not been publicly disclosed.
Bezuclastinib (CGT9486; formerly PLX9486)
| Attribute | Detail |
|---|---|
| Modality | Oral small-molecule, highly selective type-I tyrosine kinase inhibitor |
| Target | KIT exon 17 mutations, principally KIT D816V; also active against exon 17 secondary resistance mutations in GIST |
| Design intent | Minimal central-nervous-system penetration and high selectivity, intended to avoid the cognitive and bleeding adverse events associated with less selective KIT inhibitors |
| Origin | Discovered at Plexxikon Inc. (Daiichi Sankyo Group); worldwide rights exclusively licensed to Kiq LLC; acquired by Cogent (then Unum) 6 July 2020 |
| Economics owed | Upfront paid; development milestones (one paid in Q1 2026) and mid- to high-single-digit royalties to Plexxikon |
| Safety database | 800+ patients dosed across single-agent and combination studies (company IR overview, 2026) |
| Regulatory designations | Breakthrough Therapy Designation (GIST, January 2026); Real-Time Oncology Review (GIST); Priority Review (GIST NDA, May 2026); Orphan Drug tax credits recognized in the company's tax footnote ($25.7 million federal orphan drug credits as of 31 Dec 2024) |
| Manufacturing | Hovione FarmaCiencia S.A. — spray-dried dispersion and tablets, commercial supply agreement effective 1 September 2026 |
Indication 1 — Second-line GIST (bezuclastinib + sunitinib)
| Attribute | Detail |
|---|---|
| Registrational trial | PEAK — global, randomized, open-label Phase 3; bezuclastinib + sunitinib vs sunitinib monotherapy in imatinib-resistant or intolerant GIST |
| Enrollment | 413 patients (enrollment completed September 2024) |
| Primary endpoint | Progression-free survival by blinded independent central review |
| Result (cutoff 30 Sep 2025) | mPFS 16.5 vs 9.2 months; HR 0.50 (95% CI 0.39–0.65; p<0.0001). ORR 46% vs 26% (p<0.0001). Overall survival immature. |
| Duration of therapy | Estimated mean 21.4 months on the bezuclastinib arm based on patients ongoing at 31 March 2026 |
| Exon 9 subgroup | 25.1-month mPFS in 32 patients with detectable exon 9 mutations |
| Safety | Well tolerated; no unique risks versus the known sunitinib profile |
| Regulatory status | NDA submitted 1 April 2026 under RTOR; accepted with Priority Review 28 May 2026; PDUFA 30 November 2026; no AdCom planned |
| Line extension | Single-arm, 40-patient PEAK extension cohort in first-line KIT exon 9 GIST with limited or no prior imatinib, measuring ORR and PFS prospectively |
Indication 2 — Non-advanced Systemic Mastocytosis (NonAdvSM), monotherapy
| Attribute | Detail |
|---|---|
| Registrational trial | SUMMIT — randomized, double-blind, placebo-controlled, global Phase 2 (registration-directed) |
| Dose | 100 mg once daily (RP2D declared February 2024) |
| Result | Statistical significance across all primary and key secondary endpoints (July 2025 top-line); clinically meaningful benefit across all symptom domains, significant improvement across 11 individual symptoms and the most severe baseline symptom; serum tryptase reduction correlating with symptom improvement — the first such demonstration in NonAdvSM; 48-week data show continued deepening of effect |
| Proprietary instrument | MS2D2, Cogent's refined patient-reported outcome measure for mastocytosis symptom severity |
| Additional data | Six posters at AAAAI 2026, including high-unmet-need subpopulations, bone mineral density and disease-modification evidence |
| Regulatory status | NDA submitted December 2025; accepted 16 March 2026; PDUFA 30 December 2026; no AdCom planned, no review issues identified |
| Extension study | "Avapritinib switch" SUMMIT extension — enrollment complete; preliminary results expected by end of 2026 |
Indication 3 — Advanced Systemic Mastocytosis (AdvSM), monotherapy
| Attribute | Detail |
|---|---|
| Registrational trial | APEX Part 2 — global, open-label, multicenter, registration-directed Phase 2 |
| Population (31 Mar 2026 cutoff) | 81 patients dosed at 150 mg, comprising 57 SM-AHN, 11 ASM, 13 MCL; 68 evaluable for the primary endpoint |
| Result | ORR (CR+CRh+PR+CI) 65% per mIWG-MRT-ECNM, including 57% achieving CR, CRh or PR as best response; 81% ORR per pure pathological response criteria. December 2025 top-line reported 57% mIWG / 80% PPR with 89% of patients achieving ≥50% bone-marrow mast-cell reduction or clearance of aggregates. |
| Regulatory status | NDA submitted 30 June 2026. PDUFA date not yet disclosed. |
Cogent Research Team — internally discovered pipeline
| Candidate | Target | Design intent | Stage as of Sep 2026 |
|---|---|---|---|
| CGT4255 | Mutant ErbB2 (HER2) | CNS-penetrant, EGFR-sparing selective mutant ErbB2 inhibitor; preclinically demonstrated ~80% brain penetrance with potent coverage of key mutations | Phase 1 dose escalation initiated (announced Q1 2026); dose escalation to complete |
| CGT6297 | PI3Kα (H1047R-selective) | Mutant-selective PI3Kα inhibitor designed for high target engagement without the metabolic dysfunction characteristic of the class; company cited >30,000 patients per year with the driver mutation | Phase 1 dose escalation initiated (announced Q1 2026) |
| CGT1815 | Pan-KRAS(ON) | Prodrug of CGT1263, engineered to optimize human pharmacokinetics; parent shows picomolar activity across KRAS-mutant lines with selectivity over HRAS/NRAS; company disclosed outcompete data in KRAS G12D and G12V tumour-growth-inhibition models versus RMC-6236 | IND submission targeted 2026 |
| CGT1263 | KRAS(ON/OFF) | Parent molecule; selectivity profile intended to reduce the skin toxicity associated with multi-RAS inhibitors | Preclinical / IND-enabling |
| CGT1145 | JAK2 V617F | >100-fold selectivity for JAK2 V617F over wild-type JAK2 and over JAK1/3 isoforms; high oral bioavailability, low clearance across species; positioned to eradicate MPN-propagating cells and induce molecular remission with improved hematologic tolerability | IND submission targeted 2026 |
| CGT4859 | FGFR2/3 | Selective, reversible, low-nanomolar FGFR2 inhibitor; low clearance, high oral bioavailability; complete regressions at 5 mg/kg PO in AN3 CA model | Clinical programme wound down in Q1 2026 (one-time wind-down costs booked in Q1 2026 R&D) |
Flagship offering. Bezuclastinib is the only offering that matters commercially in the next 24 months. On the company's own framing, it is a potential "best-in-class KIT mutant inhibitor" across three indications.
Financial Narrative
All figures USD millions unless stated. Sources: quarterly and full-year earnings releases (Forms 8-K, Exhibit 99.1) for FY2021 through FY2025, Forms 10-K FY2021–FY2024, and Forms 10-Q for Q1 and Q2 2026.
Income statement
Notes on the EPS row. FY2021 EPS of $(1.87) was reported on a single-class basis. FY2022 and FY2023 were subsequently revised to the two-class method treating Series A and Series B Preferred as participating classes of common: revised FY2022 common EPS $(1.73) on 58,739,713 weighted shares (versus $(2.39) as originally reported), and revised FY2023 common EPS $(1.94) on 79,657,942 weighted shares (versus $(2.42) as originally reported). This restatement is disclosed in the FY2024 Form 10-K EPS tables and is the single most material presentational restatement in the review period. Zeros are placed in the FY2025 EPS and share-count cells for charting integrity; they should be read as "not disclosed in sources reviewed," not as literal zeros.
Revenue CAGR. Undefined — revenue is zero in all periods. The economically meaningful analogue is operating-expense CAGR: total opex grew from $75.5 million in FY2021 to $333.4 million in FY2025, a four-year CAGR of 45.0%.
Balance sheet
FY2023, FY2024 and FY2025 accumulated deficits are analyst computations rolling forward the FY2022 disclosed accumulated deficit of $411.2 million (Form 10-K FY2022) by each year's reported net loss; they are not direct quotations from the filings. Goodwill and intangibles are shown as zero: no goodwill or capitalized intangible balance was identified in the sources reviewed, consistent with a company that has expensed all in-process R&D. Total debt at FY2025 is the $230.0 million principal of the 1.625% Convertible Senior Notes due 2031; the $54.8 million term facility was repaid in Q4 2025 with a $7.2 million extinguishment loss.
Cash flow
As a directional proxy, FY2025 cash used in operations approximates the $328.9 million net loss less $46.1 million of non-cash stock compensation and the $7.2 million non-cash extinguishment loss, i.e. roughly $275 million — an analyst estimate, not a company figure. Dividends and buybacks are genuinely zero: Cogent has never paid a dividend and has never authorized a repurchase programme.
FY2024 equity raised is the $225.0 million February 2024 PIPE (excluding the $25.0 million ATM completed February 2025). FY2025 equity raised of $570.0 million comprises the July 2025 upsized public offering ($215.8 million net, gross not separately disclosed in sources reviewed and shown here at approximately the net figure grossed to the offering size), the November 2025 9,677,420-share offering at $31.00 ($300.0 million gross), and ATM sales; the combined November equity-plus-converts net proceeds were $546.8 million, and the July offering netted $215.8 million.
Ratios
ROIC for FY2025 uses average equity plus average debt. Net debt/EBITDA is undefined and shown as zero because both net debt and EBITDA are negative. Interest coverage of -108.9x for FY2025 divides the $333.4 million operating loss by $3.1 million of interest expense — a mechanically calculable but economically meaningless figure for a pre-revenue issuer whose interest income exceeds its interest expense by roughly 5x. Asset turnover and cash conversion cycle are not meaningful in the absence of revenue, receivables, inventory or payables cycles tied to sales; they are shown as zero.
Commentary on trends, inflections and drivers
R&D. The single defining financial inflection of the period is the 2021–2022 doubling of R&D from $55.9 million to $121.6 million as the Phase 3 PEAK trial launched and SUMMIT and APEX scaled. Growth then decelerated in every subsequent year — 42.9%, 33.9%, 15.9% — as the three registrational trials completed enrollment (PEAK in September 2024, SUMMIT in Q1 2025). Q1 and Q2 2026 R&D of $75.4 million and $70.8 million show the line flattening and beginning to roll over, with FY2026 R&D on pace for roughly $290 million. Management flagged two distinctive components of 2026 R&D: one-time FGFR wind-down costs in Q1, and pre-approval manufacturing costs that "will be capitalized following anticipated FDA approval" (Q2 2026 release). That second item matters: on approval, a slice of what is currently expensed becomes inventory on the balance sheet, which will mechanically flatter reported R&D in 2027 while consuming the same cash.
G&A. The commercial build is now the dominant cost driver. G&A rose 46.9% in FY2025 to $63.6 million, then 137% year on year in Q1 2026 ($28.2 million vs $11.9 million) and 138% in Q2 2026 ($31.8 million vs $13.4 million). Annualizing Q2 implies an FY2026 G&A run-rate above $125 million — roughly double FY2025 — before a single dollar of revenue. This is the classic pre-launch operating-leverage trough, and it is the reason the net loss is still widening even as R&D plateaus.
Net loss. Losses have compounded at 46% annually from $72.3 million (FY2021) to $328.9 million (FY2025), and 1H26 alone is $193.8 million versus $145.5 million in 1H25. The FY2025 figure was inflated by two non-recurring items: the $7.2 million loss on extinguishing the term facility and approximately $38.5 million of one-time performance-based equity compensation triggered by maximum-level PSU vesting after the PEAK readout.
Interest income. Worth isolating: $14.7 million in FY2025 and already $15.1 million in 1H26 alone, reflecting the post-financing cash pile earning at prevailing short rates. At $792 million of investments, interest income now offsets roughly a full quarter's G&A.
Balance sheet transformation. Cash rose from $287.1 million at end-2024 to $900.8 million at end-2025 — a 214% increase driven entirely by two financings executed within days of positive Phase 3 data. Total assets nearly tripled; equity rose from $256.3 million to $636.4 million despite a $328.9 million loss, which is the arithmetic of raising $800 million against a $329 million burn. Total liabilities rose from $71.6 million to $301.2 million, essentially all of it the new convertible. By 30 June 2026 cash had drawn down to $792.3 million and equity to $532.4 million; the company added $73.6 million gross via ATM in July, taking pro-forma cash to $865.9 million.
Capital discipline observation. Cogent has run a textbook "raise into strength" playbook — February 2024 PIPE at a 37% premium after positive SUMMIT Part 1b, July 2025 upsized offering after SUMMIT top-line, November 2025 dual offering at $31.00 after PEAK. Each raise was priced above the prior. The cost has been dilution: weighted average common shares grew from 38.7 million in FY2021 to 103.9 million in FY2024 and approximately 173.6 million today — a 4.5x increase in five years.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total revenue (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Single-segment revenue — Precision Therapies (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Segment operating income (USD Mn) | -75.5 | -147.8 | -208.1 | -275.9 | -333.4 |
Segment operating margin (%) | 0 | 0 | 0 | 0 | 0 |
Segment share of total revenue (%) | 0 | 0 | 0 | 0 | 0 |
Revenue by Segment and Revenue by Segment (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Research and development (USD Mn) | 55.9 | 121.6 | 173.8 | 232.7 | 269.8 |
General and administrative (USD Mn) | 19.6 | 26.2 | 34.4 | 43.3 | 63.6 |
Total operating expenses (USD Mn) | 75.5 | 147.8 | 208.1 | 275.9 | 333.4 |
R&D as share of total opex (%) | 74.0 | 82.3 | 83.5 | 84.3 | 80.9 |
G&A as share of total opex (%) | 26.0 | 17.7 | 16.5 | 15.7 | 19.1 |
R&D YoY growth (%) | 117.6 | 117.6 | 42.9 | 33.9 | 15.9 |
G&A YoY growth (%) | 12.6 | 33.7 | 31.2 | 25.9 | 46.9 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Gross profit (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Research and development expense (USD Mn) | 55.9 | 121.6 | 173.8 | 232.7 | 269.8 |
General and administrative expense (USD Mn) | 19.6 | 26.2 | 34.4 | 43.3 | 63.6 |
Total operating expenses (USD Mn) | 75.5 | 147.8 | 208.1 | 275.9 | 333.4 |
Operating income (USD Mn) | -75.5 | -147.8 | -208.1 | -275.9 | -333.4 |
Stock-based compensation (USD Mn) | 11.7 | 18.4 | 30.6 | 39.7 | 46.1 |
EBITDA, approx. operating loss plus SBC and D&A (USD Mn) | -63.8 | -129.4 | -177.5 | -236.2 | -287.3 |
Interest income (USD Mn) | 0 | 4.0 | 13.1 | 18.1 | 14.7 |
Interest expense (USD Mn) | 0 | 0 | 0 | 0 | -3.1 |
Loss on debt extinguishment (USD Mn) | 0 | 0 | 0 | 0 | -7.2 |
Change in fair value of CVR liability (USD Mn) | 0 | 1.4 | 1.7 | 0 | 0 |
Total other income, net (USD Mn) | 3.2 | 7.6 | 15.7 | 20.1 | 4.4 |
Pre-tax income (USD Mn) | -72.3 | -140.2 | -192.4 | -255.9 | -328.9 |
Income tax expense/benefit (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Net income/(loss) (USD Mn) | -72.3 | -140.2 | -192.4 | -255.9 | -328.9 |
EPS, basic and diluted, common (USD) | -1.87 | -1.73 | -1.94 | -1.94 | 0 |
Weighted average common shares (millions) | 38.7 | 58.7 | 79.7 | 103.9 | 0 |
Dividends per share (USD) | 0 | 0 | 0 | 0 | 0 |
Gross margin (%) | 0 | 0 | 0 | 0 | 0 |
Operating margin (%) | 0 | 0 | 0 | 0 | 0 |
Net margin (%) | 0 | 0 | 0 | 0 | 0 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Cash, cash equivalents and marketable securities (USD Mn) | 0 | 259.3 | 273.2 | 287.1 | 900.8 |
Total assets (USD Mn) | 0 | 300.8 | 313.4 | 327.9 | 937.6 |
Total liabilities (USD Mn) | 0 | 45.1 | 55.6 | 71.6 | 301.2 |
Total stockholders' equity (USD Mn) | 0 | 255.7 | 257.8 | 256.3 | 636.4 |
Working capital (USD Mn) | 0 | 238.1 | 232.6 | 240.8 | 846.4 |
Total debt, principal (USD Mn) | 0 | 0 | 0 | 0 | 230.0 |
Short-term debt (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Long-term debt (USD Mn) | 0 | 0 | 0 | 0 | 230.0 |
Net debt / (net cash) (USD Mn) | 0 | -259.3 | -273.2 | -287.1 | -670.8 |
Goodwill and intangibles (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Accumulated deficit (USD Mn) | 0 | 411.2 | 603.6 | 859.5 | 1,188.4 |
Balance Sheet — Net cash used in operating activities
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Net cash used in operating activities (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Capital expenditure (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Free cash flow (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Dividends paid (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Net equity capital raised, gross (USD Mn) | 0 | 0 | 0 | 225.0 | 570.0 |
Net debt capital raised, gross (USD Mn) | 0 | 0 | 0 | 0 | 230.0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Return on equity (%) | 0 | -54.8 | -74.9 | -99.5 | -73.7 |
Return on assets (%) | 0 | -46.6 | -62.7 | -79.7 | -52.0 |
Return on invested capital (%) | 0 | -54.8 | -74.9 | -99.5 | -38.0 |
Debt to equity (x) | 0 | 0 | 0 | 0 | 0.36 |
Net debt to EBITDA (x) | 0 | 0 | 0 | 0 | 0 |
Interest coverage (x) | 0 | 0 | 0 | 0 | -108.9 |
Asset turnover (x) | 0 | 0 | 0 | 0 | 0 |
Cash burn to year-end cash (x) | 0 | 0.54 | 0.70 | 0.89 | 0.37 |
Cash runway at year-end burn (years) | 0 | 1.8 | 1.4 | 1.1 | 2.7 |
Geographic Revenue
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Americas revenue (USD Mn) | 0 | 0 | 0 |
EMEA revenue (USD Mn) | 0 | 0 | 0 |
APAC revenue (USD Mn) | 0 | 0 | 0 |
Total revenue (USD Mn) | 0 | 0 | 0 |
Operating Metrics (count)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
SUMMIT global clinical sites (count) | 40 | 0 | 0 |
PEAK Phase 3 patients enrolled, global (count) | 0 | 413 | 413 |
APEX patients dosed at 150 mg (count) | 0 | 0 | 81 |
Valuation Snapshot
| Metric | Value | As of |
|---|---|---|
Closing price | $33.41 | 11 Sep 2026 |
After-hours price | $33.33 | 11 Sep 2026 |
Day's range | $33.21 – $35.00 | 11 Sep 2026 |
52-week range | $11.60 – $43.73 | Sep 2026 |
Market capitalization | $5.80 billion (+225.4% year on year) | 11 Sep 2026 |
Shares outstanding | 173.57 million | Latest reported |
Beta | 0.31 (StockAnalysis); 1.19 reported by an alternative source in Dec 2025 — sources conflict | 2,026 |
Average daily volume | 1,715,801 shares traded 11 Sep 2026; ~3.2 million average reported Dec 2025 | 2,026 |
Capital Markets
| Metric | 1-year | 3-year | 5-year | Since IPO |
|---|---|---|---|---|
COGT total return (%) | 225.4 | 0 | 233.4 | 320.0 |
S&P 500 total return (%) | 0 | 0 | 86.6 | 120.0 |
Capital Markets — Price/Book
| Metric | Cogent (COGT) | Comment |
|---|---|---|
Price/Book | ~10.9x | $5.80B market cap over $532.4M stockholders' equity at 30 Jun 2026 (analyst calculation). A third-party source reported 13.88x at an earlier date. |
Enterprise value | ~$5.24 billion | $5.80B equity + $0.23B convertible principal – $0.79B cash at 30 Jun 2026 (analyst calculation) |
EV per NDA under review | ~$1.75 billion | Analyst construct: three NDAs pending |
Valuation Snapshot — Consensus rating
| Metric | Value |
|---|---|
Consensus rating | Strong Buy |
Number of covering analysts | 12 |
Average 12-month price target | $55.82 (+67.1% versus $33.41) |
Highest published target | $62 (JPMorgan, Overweight, added to Analyst Focus List ~9–10 Sep 2026) |
Recent target revisions | Piper Sandler to $55 from $52 (17 Aug 2026, Overweight); H.C. Wainwright to $55 from $52 (Aug 2026, Buy); Guggenheim to $52 from $45 (Aug 2026, Buy); Wedbush Buy reiterated (11 Aug 2026) |
Consensus EPS trajectory | Loss per share of ~$(2.41)–$(2.46) in the current year, improving to ~$(2.24) next year on one third-party model — i.e. no consensus expectation of profitability within three years |
Capital Instruments
| Instrument | Principal (USD Mn) | Coupon | Maturity | Carrying value at 30 Jun 2026 (USD Mn) | Conversion terms |
|---|---|---|---|---|---|
Convertible Senior Notes | 230.0 | 1.625% | 15 November 2031 | 223.5 | Initial conversion price ~$44.95 per share; settlement in cash, shares or a combination at Cogent's election; holder conversion unrestricted from 15 August 2031 |
Term loan facility | 0 | — | Repaid Q4 2025 | 0 | $54.8 million repaid; $7.2 million extinguishment loss |
Capital Markets Data
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
Scheduled debt maturities (USD Mn) | 0 | 0 | 0 | 0 | 0 | 230 |
Cash interest payable (USD Mn) | 3.7 | 3.7 | 3.7 | 3.7 | 3.7 | 3.7 |
Analyst Conclusions
Management guidance
| Guidance item | Company statement | Source |
|---|---|---|
| Cash runway | Into late 2028, including through potential FDA approvals in GIST, NonAdvSM and AdvSM and early commercial launch activities | Q2 2026 release, 10 Aug 2026 |
| GIST approval | PDUFA target action date 30 November 2026 | 28 May 2026 |
| NonAdvSM approval | PDUFA target action date 30 December 2026 | 16 Mar 2026 |
| AdvSM | NDA submitted 30 June 2026; acceptance and PDUFA pending | 30 Jun 2026 |
| Launch | Bezuclastinib launch in the second half of 2026, pending approval | Repeated in every 2026 release |
| Commercial organization | Up to 100 employees inclusive of home office and field-based; fully onboarded as of August 2026 | 2026 proxy; Q2 2026 release |
| SUMMIT extension | Preliminary "avapritinib switch" results by end of 2026 | Q2 2026 release |
| Pipeline | IND submissions for CGT1815 (pan-KRAS(ON)) and CGT1145 (JAK2 V617F); completion of CGT4255 dose escalation | Q2 2026 release |
Cogent provides no revenue, margin or earnings guidance. The complete set of quantified forward commitments is:
Consensus growth expectations
Twelve covering analysts rate the shares Strong Buy with an average target of $55.82. Third-party consensus models show a loss per share of roughly $(2.41) in the current year improving modestly to $(2.24) next year, with no profitability forecast within three years. In other words, the sell side is underwriting a launch, not an earnings inflection. The gap between the $33.41 price and the $55.82 target — 67% — is the market's aggregate discount for PDUFA and launch risk.
Bull case
-
Three approvals inside seven months would create the only multi-indication independent KIT franchise. The FDA has stated in both acceptance letters that it plans no advisory committee and has identified no review issues — unusually clean language. Approval on 30 November and 30 December 2026 converts Cogent from a binary story into a revenue company with two prescriber channels and a third indication following.
-
The GIST data are commercially decisive, not merely statistically significant. A hazard ratio of 0.50 against an active comparator, a 46% versus 26% ORR, and a 21.4-month estimated mean treatment duration in a setting with no new therapy in twenty years produce both rapid adoption and high revenue per patient. Management reported "strong physician and patient enthusiasm and a rapid uptake expected upon approval." Ayvakit's trajectory — $479 million in 2024 to $700–720 million guided for 2025 with "extremely low" penetration — is the template for what a differentiated KIT asset can do commercially.
-
The balance sheet removes financing risk from the launch equation. $865.9 million pro forma, $400 million of additional ATM capacity, a single $230 million convertible not due until 2031 with a sub-$4 million cash coupon, and interest income exceeding interest expense by roughly 5x. Cogent can execute a self-commercialized dual launch, fund three Phase 1 programmes, and file two new INDs without approaching the market from weakness — and it retains 100% of ex-U.S. rights as unmonetized optionality.
Bear case
-
The valuation already embeds successful approval and a successful launch. At a $5.2 billion enterprise value with zero revenue, roughly $1.75 billion is being paid per pending NDA. A complete response letter on either the 30 November or 30 December PDUFA would be catastrophic to the multiple, and the two dates fall thirty days apart — there is no diversification in the timing.
-
Sanofi and GSK have converted this from a white-space opportunity into a contested category. Ayvakit is entrenched with roughly $700 million of run-rate revenue and a parent with global rare-disease infrastructure; elenestinib is in registrational development behind it. In GIST, GSK's StrateGIST-3 is running the same PFS endpoint against the same comparator with $1.1 billion already committed. Cogent must win a two-front war as a first-time commercial organization whose entire field force was hired in the last eighteen months.
-
The cost curve is fully loaded and the dilution is relentless. G&A grew 137–138% year on year in each of the first two quarters of 2026 with no revenue; 1H26 net loss was $193.8 million. Weighted average shares have risen 4.5x since FY2021, Fairmount sold 7,000,000 shares at $34.66 in March 2026 — above today's price — and a $400 million ATM was announced in August despite $865.9 million of liquidity. Management is telling the market, through its own capital actions, that it expects to need more money.
Catalysts and monitorables, next twelve months
| Date | Catalyst | Why it matters |
|---|---|---|
| Q4 2026 (pending) | FDA acceptance decision and PDUFA assignment for the AdvSM NDA | Completes the three-indication regulatory picture |
| 30 Nov 2026 | GIST PDUFA | First approval opportunity; Priority Review |
| 30 Dec 2026 | NonAdvSM PDUFA | The chronic-dosing, highest-lifetime-value indication |
| By end-2026 | Preliminary "avapritinib switch" SUMMIT extension results | The single most competitively important dataset — evidence for converting Ayvakit patients |
| Q4 2026 – Q1 2027 | U.S. list price disclosure and payer coverage decisions | First real read on gross-to-net and access friction |
| Q1 2027 | First full quarter of bezuclastinib net product revenue | Converts the thesis from binary to executional |
| 2026–2027 | IND submissions for CGT1815 (pan-KRAS(ON)) and CGT1145 (JAK2 V617F) | Tests whether the Boulder discovery engine can produce a second franchise |
| 2,027 | Completion of CGT4255 dose escalation; initial CGT6297 data | First clinical proof points for internally discovered molecules after the FGFR wind-down |
| Ongoing | PEAK first-line exon 9 extension cohort enrollment and early data | Potential upstream label expansion into a larger population |
| Ongoing | GSK StrateGIST-3 enrollment progress and any interim disclosure | Determines the length of the GIST exclusivity window |
| Ongoing | Sanofi Ayvakit quarterly revenue and elenestinib regulatory progress | The competitive benchmark against which Cogent's SM launch will be judged |
| Ongoing | ATM utilization against the $400 million programme | Reveals management's true confidence in the runway guidance |
| December 2026 | Annual compensation review and equity grant cycle | First post-approval alignment decision; watch the new peer group |
Concluding analyst verdict
Cogent Biosciences arrives at September 2026 in the rarest position in biotechnology: a company that has done everything it said it would do, in the order it said it would do it, and is now waiting on two dates thirty days apart. Three pivotal trials read out positively within five months of 2025. Three NDAs were filed within seven months. Two have been accepted with no advisory committee and no identified review issues, one with Priority Review. The balance sheet was rebuilt from $287 million to $866 million by raising into strength three separate times, and the resulting capital structure — a single $230 million convertible not due until 2031, at a coupon comfortably covered by interest income — is the cleanest in the peer group. The commercial organization is hired. The supply agreement is signed. There is very little left to do except sell the drug.
That is also the problem. The market is being asked to pay $5.2 billion of enterprise value for an asset that has never generated a dollar, in two categories where the competition consolidated into Sanofi and GSK inside eighteen months. Ayvakit is not a weak incumbent; it is a $700 million product with a global parent and a next-generation successor in registrational development. GSK is running a PFS-powered Phase 3 against the same comparator Cogent beat. And Cogent's own actions betray some caution: a $400 million ATM announced against $866 million of cash is not the behaviour of a management team certain that runway guidance holds.
The honest characterization is that the clinical risk has largely been retired and the commercial risk has barely been touched. The 67% gap between the $33.41 share price and the $55.82 consensus target is the market pricing that distinction correctly. Bezuclastinib's data — a 0.50 hazard ratio, 46% versus 26% ORR, 21.4-month treatment duration, 65% ORR in AdvSM, symptom benefit across every domain in NonAdvSM — are strong enough that approval is the base case and rapid uptake in GIST is plausible. Systemic mastocytosis is the harder fight and the bigger prize, and the "avapritinib switch" readout due by year-end will tell more about the terminal value of this franchise than either PDUFA date. Watch that study, watch the first two quarters of net product revenue, and watch how quickly the ATM is drawn. Those three data series will settle whether Cogent is a $5 billion company that grows into its valuation or a $5 billion company that was priced for a launch it could not execute.
Prepared from publicly available sources: SEC filings (Forms 10-K, 10-Q, 8-K, DEF 14A, ARS, FWP, Schedule 13D/A), company press releases and investor materials, counterparty disclosures (Sanofi, GSK), and market data providers, all accessed 13 September 2026. Where sources conflict — notably on shares outstanding, beta, and FY2025 earnings per share — both figures and the discrepancy are stated. This document is analytical in nature and is not investment advice.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Age | Since | Prior roles | Education |
|---|---|---|---|---|---|
Andrew Robbins | Chief Executive Officer, President and Director | 50 | October 2020 | COO, Array BioPharma (Mar 2015–Jul 2019, through Pfizer acquisition); SVP Commercial Operations, Array (2012–2015); GM/VP US Alternate Site and VP Corporate Development, Hospira (2007–2012); commercial roles, Pfizer Oncology | M.B.A., Kellogg School of Management, Northwestern University; B.A., Swarthmore College |
John Green | Chief Financial Officer, principal financial and accounting officer | 45 | July 2020 | VP Finance and Controller, Cogent/Unum (2018–2020); Principal Accounting Officer, Merrimack Pharmaceuticals (2017–2018) | Chartered Professional Accountant; B.S. Chemistry and Biology, Acadia University |
Jessica Sachs, M.D. | Chief Medical Officer | 51 | June 2019 | VP Clinical Sciences, Unum (2017–2019); Senior Medical Director Clinical Research, Takeda (2012–2017); Associate Director, Genzyme (2010–2012); Harvard Medical School faculty since 2007; Assistant in Pediatrics, Mass General | M.D., Washington University in St. Louis; B.S., Duke University; fellowship, Dana-Farber / Boston Children's |
John Robinson, Ph.D. | Chief Scientific Officer | 52 | April 2021 | VP Medicinal Chemistry, Pfizer Boulder R&D (2019–2021); Executive Director and Head of Chemistry, Array BioPharma (2002–2019) | Ph.D. Synthetic Organic Chemistry, University of Delaware; B.S. Biochemistry, Indiana University of Pennsylvania |
Cole Pinnow | Chief Commercial Officer | 51 | May 2024 | Global Franchise Lead GU/Lung/Breast Oncology, Pfizer (2022–2024); President, Pfizer Canada (2020–2022); Pfizer Essential Health and Hospital Businesses Canada (2018–2019); VP U.S. commercial business unit, Pfizer (2015–2018); Hospira (2004–2015) | M.B.A., Chicago Booth; M.S. Microbiology, Iowa State; B.A. Biology, St. Olaf College |
Evan Kearns | Chief Legal Officer and Corporate Secretary | 45 | May 2021 | VP, General Counsel, Corporate Secretary and Chief Compliance Officer, Agenus (2018–2021); associate, Goodwin Procter LLP | J.D., University of Toledo College of Law; B.A. Economics, Colby College |
Peter Harwin | III | 40 | July 2020 | Yes — Chairman | Nominating; Science |
Andrew Robbins | III | 50 | October 2020 | No (CEO) | — |
Karen Ferrante, M.D. | I | 68 | February 2018 | Yes | Nominating (Chair); Science |
Matthew E. Ros | I | 59 | July 2019 | Yes | Audit; Nominating |
Chris Cain, Ph.D. | II | 42 | July 2020 | Yes | Compensation; Science (Chair) |
Arlene M. Morris | II | 74 | July 2019 | Yes | Audit; Compensation (Chair) |
Todd Shegog | II | 61 | February 2021 | Yes | Audit (Chair); Compensation |
Directors' Remuneration
| Metric | FY2024 | FY2025 |
|---|---|---|
Audit fees (USD K) | 1,135 | 1,491 |
Audit-related fees (USD K) | 0 | 0 |
Tax fees (USD K) | 281.4 | 219.0 |
All other fees (USD K) | 2 | 2 |
Total fees (USD K) | 1,418.4 | 1,712.0 |
Executive Leadership Team by Name and Position
| Name and position | Year | Salary (USD) | Bonus (USD) | Stock awards (USD) | Option awards (USD) | Non-equity incentive (USD) | All other (USD) | Total (USD) |
|---|---|---|---|---|---|---|---|---|
Andrew Robbins, CEO | 2025 | 724,554 | 21,600 | 12,993,250 | 13,447,680 | 561,600 | 14,000 | 27,762,684 |
Andrew Robbins, CEO | 2024 | 692,000 | 0 | 0 | 3,734,610 | 477,480 | 13,800 | 4,917,890 |
Andrew Robbins, CEO | 2023 | 656,098 | 0 | 1,873,200 | 4,962,615 | 393,659 | 13,200 | 7,898,772 |
John Green, CFO | 2025 | 510,677 | 11,467 | 3,965,750 | 3,746,304 | 298,131 | 14,000 | 8,546,329 |
John Green, CFO | 2024 | 490,025 | 0 | 0 | 1,018,530 | 225,412 | 13,800 | 1,747,767 |
Jessica Sachs, CMO | 2025 | 549,389 | 12,342 | 4,535,250 | 3,746,304 | 320,892 | 14,000 | 9,178,177 |
Jessica Sachs, CMO | 2024 | 527,436 | 0 | 0 | 1,018,530 | 272,948 | 13,800 | 1,832,714 |
Directors' Remuneration (2024 salary (USD)–Dec 2025 salary (USD))
| Name | 2024 salary (USD) | Jan 2025 salary (USD) | Dec 2025 salary (USD) |
|---|---|---|---|
Andrew Robbins | 692,000 | 720,000 | 812,000 |
John Green | 490,025 | 509,626 | 537,000 |
Jessica Sachs | 527,436 | 548,533 | 573,217 |
John Robinson | 510,775 | 531,206 | 555,110 |
Cole Pinnow | 460,000 | 478,400 | 554,000 |
Directors' Remuneration by Name
| Name | Fees earned in cash (USD) | Option awards (USD) | Total (USD) |
|---|---|---|---|
Peter Harwin | 92,500 | 184,615 | 277,115 |
Todd Shegog | 72,500 | 184,615 | 257,115 |
Arlene M. Morris | 70,000 | 184,615 | 254,615 |
Chris Cain | 67,500 | 184,615 | 252,115 |
Karen Ferrante | 62,500 | 184,615 | 247,115 |
Matthew E. Ros | 60,000 | 184,615 | 244,615 |
Major Shareholders
| Holder | Shares | Reported value (USD K) | Approx. % of shares outstanding |
|---|---|---|---|
FMR LLC (Fidelity) | 23,086,967 | 820,049 | 13.3 |
BlackRock, Inc. | 12,974,591 | 460,857 | 7.5 |
Vanguard Group Inc. | 11,514,326 | 408,989 | 6.6 |
Deerfield Management Company L.P. (Series C) | 9,043,903 | 321,239 | 5.2 |
Fairmount Funds Management LLC | 9,003,418 | 319,801 | 5.2 |
RTW Investments, LP | 7,592,241 | 269,676 | 4.4 |
Kynam Capital Management, LP | 6,165,223 | 218,989 | 3.6 |
TCG Crossover Management, LLC | 5,868,162 | 208,437 | 3.4 |
State Street Corp | 4,940,300 | 175,479 | 2.8 |
Janus Henderson Group Plc | 4,537,408 | 161,115 | 2.6 |
Geode Capital Management, LLC | 3,514,562 | 124,862 | 2.0 |
Competitive Landscape
Peer Comparison FY2026
| Metric | Cogent Biosciences | Sanofi (Blueprint SM franchise) | GSK (IDRx/GIST) | ONO (Deciphera GIST) |
|---|---|---|---|---|
Relevant product revenue, FY2024 (USD Mn) | 0 | 479 | 0 | 0 |
Relevant product revenue, FY2025 guidance/est. (USD Mn) | 0 | 710 | 0 | 0 |
Relevant product revenue, FY2026 est. (USD Mn) | 0 | 0 | 0 | 0 |
R&D intensity, R&D as % of own revenue | 0 | 0 | 0 | 0 |
Approved KIT products | 0 | 1 | 0 | 1 |
Pivotal readouts delivered 2025 | 3 | 0 | 0 | 0 |
Enterprise value attributable to the KIT franchise (USD Bn) | 5.2 | 9.1 | 1.1 | 0 |
Recent Developments
--



